TITLE

Can Antiarrhythmic Agents be Selected Based on Mechanism of Action?

AUTHOR(S)
Lau, W.; Newman, D.; Dorian, P.
PUB. DATE
December 2000
SOURCE
Drugs;Dec2000, Vol. 60 Issue 6, p1315
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
When selecting an antiarrhythmic agent the clinician needs to be able to accurately predict the probability that a particular drug will serve its intended purpose in a given patient. This is difficult because of the complexity of variables which govern the relationship between drug administration and clinical outcome. The efficacy of a drug may potentially be predicted from its mechanism of action. At least two classifications of antiarrhythmic agents based on mechanism of action have been proposed. The Vaughan Williams classification is based on the predominant electrophysiological effects of a drug on the action potential. In the Sicilian Gambit approach, a number of potential targets (‘vulnerable parameters’) for drug action are identified and antiarrhythmic drugs or substances that affect cardiac electrophysiology are characterised by their actions on each of these. The usefulness of these classification systems in predicting antiarrhythmic drug efficacy are limited. Furthermore, in the Vaughan Williams classification not all drugs in the same class have identical effects, whereas some drugs in different classes have overlapping actions. The Sicilian Gambit requires in-depth knowledge regarding cellular and molecular targets of antiarrhythmic agents which may make it intimidating or simply impractical for regular clinical use. Surrogate measures such as 24-hour Holter monitoring and programmed electrical stimulation have been used to predict anti-arrhythmic drug efficacy. However, studies such the Cardiac Arrhythmia Suppression Trial (CAST) have shown that suppression of ventricular ectopy on Holter monitoring does not necessarily correlate with improved survival and may in fact be dangerous. Conversely, studies using programmed electrical stimulation to assess drug effect on variables such as tachycardia inducibility, refractory period and ventricular tachycardia cycle length show that suppression of tachycardia inducibility, prolongation of refractory period and prolongation of ventricular tachycardia cycle length, are all associated with reduced recurrence of tachycardia and possibly improved survival. The most practical use of the current classification systems applied to antiarrhythmic agents may be in their ability to predict with reasonable accuracy, the risk and type of proarrhythmia based on the mechanism of action of an agent.
ACCESSION #
9592879

 

Related Articles

  • Amiodarone reduces deaths in CHF patients with high heart rates. Nul, D. R.; Doval, H. C.; Leibovitch, Eric R. // Formulary;Sep97, Vol. 32 Issue 9, p996 

    Investigates on the how antiarrhytmic amiodarone reduces mortality in patients with severe congestive heart failure. Effect of drug on percentage of mortality; Recommendation of authors on use of drug.

  • Therapeutic Drug Monitoring of Antiarrhythmic Drugs. Jürgens, Gesche; Graudal, Niels A.; Kampmann, Jens P. // Clinical Pharmacokinetics;May2003, Vol. 42 Issue 7, p647 

    Most antiarrhythmic drugs fulfil the formal requirements for rational use of therapeutic drug monitoring, as they show highly variable plasma concentration profiles at a given dose and a direct concentration-effect relationship. Therapeutic ranges for antiarrhythmic drugs are, however, often...

  • Vernakalant, amioderone-like drugs move forward through clinical trials. Raible, Eric // Cardiology Today;Mar2009, Vol. 12 Issue 3, p15 

    The article reports on the preliminary data presented by cardiologist A. John Camm during the 14th Annual Boston Atrial Fibrillation Symposium in Boston, Massachusetts on January 15-17, 2009 which revealed that several antiarrhythmic drugs in later-stage trials show promising results.

  • Prescribing and monitoring pearls for atrial antiarrhythmic therapies. Serra, Michael // Cardiology Today;Dec2010, Vol. 13 Issue 12, p30 

    The article outlines pointers and things to consider when prescribing and monitoring antiarrthythmic agents.

  • Is Gender a Risk Factor for Adverse Drug Reactions?: The Example of Drug-Induced Long QT Syndrome. Drici, M-D.; Clément, N. // Drug Safety;Jun2001, Vol. 24 Issue 8, p575 

    Drug-induced torsade de pointes is a rare life-threatening adverse drug reaction (ADR) which is strongly influenced by gender. Drugs that prolong cardiac repolarisation include antiarrhythmics, gastrokinetics, antipsychotics, antihistamines and antibacterials. Such drugs share the potential to...

  • Procainamide.  // Reactions Weekly;2/13/2010, Issue 1288, p33 

    The article describes a case of ventricular tachycardia induced by the administration of intravenous procainamide in a 32-year-old man with type 1 muscular dystrophy.

  • Sotalol.  // Reactions Weekly;8/6/2011, Issue 1363, p38 

    The article describes the case of two pregnant women who experienced QT interval prolongation after receiving sotalol for atrial tachyarrhythmias.

  • Flecainide overdose.  // Reactions Weekly;May2015, Vol. 1549 Issue 1, p117 

    The article presents a case study of a 50-year-old man who developed altered mental status, diarrhoea, cardiac arrest, abdominal pain, type 1 Brugada pattern, a QRS prolongation and a QTc prolongation after flecainide overdose and toxicity.

  • Dronedarone.  // Reactions Weekly;10/16/2010, Issue 1323, p19 

    The article describes the case of a 47-year-old man who experienced worsening heart failure leading to acute renal and liver failure after starting dronedarone therapy.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics